lundi 3 juin 2019

Onco Actu du 3 juin 2019 - spécial ASCO


ASCO 2019: Abstracts With High Impact Potential [OBR]

ASCO 2019 news: pancreatic cancer precision, choices for prostate cancer and a(nother) blood test [Cancer Research UK]

Drugs make headway against lung, breast, prostate cancers [AP]


Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs [STAT]

5.5.10 ASCO (HÉMATO)

Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019 [Celgene]

ASCO: Sanofi's anti-CD38 combo boosts responses, extends lives in advanced multiple myeloma [Fierce Biotech]

DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant [Janssen]

Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma [Janssen]

Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma [Sanofi]

#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait [EndPoints]


GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study [Grail]


AstraZeneca, Merck make case for PARP's place in pancreatic cancer [Biopharma Dive]

Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer [AstraZeneca]

Targeted drug trial points to potential ‘new age’ for pancreatic cancer treatment [Cancer Research UK]

Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer [ASCO]

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study [Reuters]


The Affordable Care Act erased a racial disparity in cancer care, a new study says [STAT]

Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation [ASCO]

Racial Disparities in Access to Timely Cancer Treatment Nearly Eliminated in States With Medicaid Expansion [ASCO]

Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma [ASCO]

5.5.2 ASCO (SEIN)

Precision drug combo boosts survival in younger women with advanced breast cancer [Cancer Research UK]

Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting [Roche]

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial [Novartis]

Novartis breast cancer drug shows survival benefit in younger women [Biopharma Dive]

Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women With Advanced Breast Cancer [ASCO]

#ASCO19: Hey Pfizer, Novartis is going after your blockbuster cancer franchise — and they have positive OS data [EndPoints]

Novartis hopes Kisqali data will help narrow gap to blockbuster rival [Reuters]

New breast cancer treatment offers hope of longer life to younger women [The Guardian]

Breast cancer drug gives new hope to young women with disease by improving survival by 50 per cent [The Telegraph]

A Drug Prolonged Life in Younger Women With Advanced Breast Cancer [NY Times]


Bayer’s darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate cancer [Bayer]

ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) [Janssen]

Adding Enzalutamide to Standard First-Line Treatment Improves Survival for Men With Metastatic Hormone-Sensitive Prostate Cancer [ASCO]

Men with prostate cancer offered hope by 'search and destroy' treatment [The Telegraph]


Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial [Merck]

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019 [Amgen]

#ASCO19: Amgen shows off their latest BCMA BiTE update with plans to hustle ahead as rivals jostle for position [EndPoints]


Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting [Merck]

For some lung cancer patients, Keytruda provides lasting benefit [Biopharma Dive]

ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survival [Fierce Pharma]

Imfinzi is the only immunotherapy to demonstrate overall survival at three years in unresectable Stage III non-small cell lung cancer [AstraZeneca]

Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases [Roche]

#ASCO19: Merck’s PD-1 star Keytruda illustrates just how powerful it can be over 5 years — with plenty of room for improvement [EndPoints]

Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer [ASCO]

Merck's Keytruda sets new five-year survival standard for advanced lung cancer [Reuters]


As ASCO begins, Iovance shows progress with cancer cell therapy [Biopharma Dive]

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia [Gilead]

Iovance comes back with another upbeat cancer trial update as #ASCO19 curtain raiser [EndPoints]

Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy [Iovance]


ASCO: Merck details Keytruda's second stomach cancer slip [Fierce Pharma]

Results Evaluating Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma to be Presented at 2019 ASCO Annual Meeting [Merck]

Immunotherapy comparable to chemo for some advanced stomach cancers [Cancer Research UK]

Front-Line Pembrolizumab Is Promising Alternative to Chemotherapy for Advanced Gastroesophageal Junction and Gastric Cancers [ASCO]


Turning Point makes push to outdo Pfizer, Roche in targeted cancer therapy [Biopharma Dive]

Turning Point Therapeutics Announces Updated Interim Clinical Data Of Repotrectinib In Advanced ROS1+ Non-Small Cell Lung Cancer [Turning Point]

Turning Point tracks an impressive ORR rate in NSCLC — but shares skid lower on second look [EndPoints]

What Will It Take To Shake The Tree And Save More Lives From Lung Cancer: A Report From ASCO 2019 [Dr. Len]


What Can Be Learned from a Negative Clinical Trial? Findings from a Sarcoma Study at ASCO 2019 [Memorial Sloan Kettering Cancer Center]